# Novo Nordisk CEO Facing Scrutiny over Drug Prices in the US – Novo Nordisk CEO, Lars Fruergaard Jorgensen, has been questioned by Congress regarding the prices of the company’s weight loss drugs, Ozempic and Wegovy, in the United States. – The scrutiny comes amidst concerns over the affordability and accessibility of these medications for individuals seeking to manage their weight. – Ozempic and Wegovy have shown promising results in aiding weight loss efforts, but the high costs have raised issues of equity and affordability for patients. ### Hot Take It is essential for pharmaceutical companies to strike a balance between innovation and accessibility when pricing medications that can potentially transform lives. The focus should be on ensuring that individuals have access to effective weight loss treatments without undue financial burden. For personalized weight loss support and guidance, contact Mindful Evolution at https://yourmindfulevolution.com or call or text us at 954-639-9960. Weight Loss Disclaimer: Individual results vary. Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.